Natera, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Natera, Inc. on May 8, 2020. The filing details a significant legal settlement and a material amendment to a supply agreement with Illumina, Inc., resolving a patent infringement dispute and restructuring their commercial relationship.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses on legal and contractual developments rather than periodic financial performance data.
Material Changes and Agreements
- Patent Settlement: Natera and Illumina settled a patent infringement action regarding U.S. Patent No. 9,493,831 and Natera's U.S. Patent No. 8,682,592. The settlement dismisses all claims related to non-invasive prenatal testing (NIPT) and pre-implantation genetic screening/diagnosis (PGS/PGD) activities prior to the settlement date.
- Supply Agreement Amendment: The parties executed a sixth amendment to their 2013 Supply Agreement, extending the term to May 8, 2030.
- Fee Reductions: Fees payable by Natera to Illumina for clinical NIPT tests using Illumina reagents will decrease starting in October 2020, with further reductions tied to volume increases.
- Intellectual Property Licenses: Natera received licenses to Illumina's IP (including a patent pool with Sequenom) for NIPT. Conversely, Natera granted Illumina a non-exclusive, perpetual worldwide license to certain Natera IP in the '592 Patent family for NIPT and PGS/PGD.
- Regulatory Timeline: The deadline for Natera to obtain FDA premarket approval for at least one in-vitro diagnostic (IVD) was extended to May 8, 2026.
- Termination Rights: Illumina's right to terminate certain rights under the agreement upon two years' prior notice was eliminated.
Outlook, Risks, and Contingencies
- Platform Flexibility: Natera is not bound to exclusively use Illumina's sequencing instruments but may face reduced discounts if volumes on the Illumina platform decline.
- Oncology Support: Illumina will offer credits for instrument purchases and contribute products to offset costs for Natera's oncology and organ transplant monitoring product development.
- Ongoing Proceedings: The settlement does not impact ongoing inter partes review proceedings at the U.S. Patent and Trademark Office or pending patent opposition proceedings in Europe.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks and uncertainties that could cause actual results to differ from current expectations.
Investor Verification Checklist
- Verify the specific fee reduction percentages and volume thresholds in the full text of the Supply Agreement Amendment.
- Confirm the scope of the "Natera Licensed IP" granted to Illumina to ensure it does not encroach on the Panorama test methodology.
- Monitor the status of the ongoing inter partes review and European patent opposition proceedings, as these remain unresolved.
- Review the upcoming Form 10-Q for the full text of the Amendment and any updated financial guidance reflecting the settlement.